Published in Clinical Advances in Hematology & Oncology, this article presents an overview of the currently available monoclonal antibody treatments in multiple myeloma (MM), discussing the clinical value, significant potential, and possible limitations of these immunotherapeutic approaches to driving deeper responses and achieving longer overall survival among patients with a challenging disease.